Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT ID: NCT00642421

Last Updated: 2010-02-09

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-02-29
• Study Completion Date: 2009-08-31

Brief Summary

The purpose of this study is to assess the safety profile of a new prolonged release formulation of octreotide acetate, C2L-OCT-01 PR, administered intra muscularly every 4, 5 or 6 weeks in acromegalic patients.

Conditions

Acromegaly

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Population A

Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.

Group Type: EXPERIMENTAL

C2L-OCT-01 PR, 10 or 20 mg

Intervention Type: DRUG

The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

Population B

Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.

Group Type: EXPERIMENTAL

C2L-OCT-01 PR, 20 mg

Intervention Type: DRUG

The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

Interventions

C2L-OCT-01 PR, 10 or 20 mg

The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

Intervention Type: DRUG

C2L-OCT-01 PR, 20 mg

The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.

Intervention Type: DRUG

Other Intervention Names

octreotide acetate; octreotide acetate

Eligibility Criteria

Inclusion Criteria

• Be greater than or equal to 18 years of age.
• Have a confirmed diagnosis of acromegaly based on the following criteria:

1. Typical clinical features and

2. Mean GH concentration > 1.0 ng/mL following an oral glucose tolerance test (OGTT) and

3. Elevated serum IGF-1 levels above gender- and age- matched values.

• Fall into one of the following categories:

1. Has been treated for at least the last 12 weeks with Sandostatin LAR® 10 mg or 20 mg, every 28 days with well-controlled symptoms of acromegaly and GH concentration < 2.5 ng/mL at screening or

2. Be naïve to prolonged release octreotide with a demonstrated tolerance response to a 7-day administration of Sandostatin® immediate release (50 µg s.c. t.i.d.) or

3. If previously treated with prolonged release octreotide, has stopped such treatment for at least 12 weeks prior to screening.

• If female and of childbearing potential, must have a negative pregnancy test at screening and be using adequate means of birth control (i.e., oral or trans-dermal contraceptive drugs, intra-uterine device, diaphragm) during the study.
• Have the ability to understand the requirements of the study, provide written informed consent to participate in this study and agree to abide by the study restrictions.

Exclusion Criteria

To be eligible for entry in this study, patient must NOT:

• If female, be pregnant or lactating.
• Have been treated with a GH receptor antagonist (pegvisomant) within the last 12 weeks.
• Have used a dopamine agonist within the last 30 days.
• Have undergone pituitary surgery within the last 12 weeks.
• Have undergone radiotherapy within the last two years.
• Have any contraindication (hypersensitivity to octreotide formulation) or non-responders to Sandostatin-LAR® treatment.
• Be currently treated with Sandostatin-LAR® and have symptoms of acromegaly that would justify, in the Investigator's opinion, a dose modification.
• Be receiving Sandostatin-LAR® administration every < 21 or > 35 days.
• Have a liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis, or has persistent ALT, AST > 2 X ULN, serum creatinine > 2 X ULN, serum bilirubin > 2 X ULN.
• Have any other conditions that could result in altered GH or IGF-1 levels (such as anorexia nervosa, Laron's syndrome, treatment with levodopa or narcotics analgesics, heroin abuse.)
• Have type I diabetes (insulin-dependent) or uncontrolled type II diabetes (non-insulin-dependent) as indicated by the presence of ketoacidosis or HbA1C greater than or equal to 10%.
• Have clinically significant signs and symptoms potentially related to a tumor compression of the optical chiasm, based on judgment of the investigator.
• Have symptomatic cholelithiasis.
• Have received an investigational drug or participated in a clinical trial within the last 30 days.
• Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ambrilia Biopharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Ambrilia Biopharma, Inc.

Principal Investigators

Raphael Naudin, M.D.

Role: STUDY_DIRECTOR

Ambrilia Biopharma, Inc.

Locations

UCLA Medical Center Division of Neurosurgery

Los Angeles, California, United States

Stanford University Medical Center

Stanford, California, United States

Kaleida Health/Diabetes Center of WNY

Buffalo, New York, United States

The Cleveland Clinic

Cleveland, Ohio, United States

VA Puget Sound Health Care System

Tacoma, Washington, United States

Republican Centre for Medical Rehabilitation and Water-therapy

Minsk, , Belarus

Semmelweis Egyetem Altalanos Orvostudomanyi

Budapest, , Hungary

Institute of Endocrinology "C.I. Parhon" Bucharest

Bucharest, , Romania

Institute of Endocrinology, University Clinical Center

Belgrade, , Serbia

V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine

Kiev, , Ukraine

Countries

United States; Belarus; Hungary; Romania; Serbia; Ukraine

Other Identifiers

C2L-OCT-01 PR-303

Identifier Type: -

Identifier Source: org_study_id